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Abstract: Sugar chain abnormalities in glycolipids and glycoproteins are associated with
various diseases. Here, we report an adult onset cardiac dilatation in a transgenic mouse line with
GalO1,3GalNAc ,2,3-sialyltransferase II (ST3Gal-II) transgenes. The transgenic hearts at the end-
stage, at around 7 months old, were enlarged, with enlarged cavities and thin, low-tensile walls,
typical of dilated cardiomyopathy. Although no apparent change was found in heart gangliosides,
glycosylation of heart proteins was altered. Interestingly, sugar moieties not directly related to the
ST3Gal-II catalytic reaction were also changed. Signiﬁcant increases in calreticulin and calnexin
were observed in hearts of the transgenic mice. These results suggest that expression of ST3Gal-II
transgenes induces abnormal protein glycosylation, which disorganizes the endoplasmic/sarcoplas-
mic reticulum quality control system and elevates the calreticulin/calnexin level, resulting in
suppression of cardiac function. The transgenic mice showed 100% incidence of adult onset cardiac
dilatation, suggesting great potential as a new model for dilated cardiomyopathy.
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Introduction
Cardiomyopathy is a serious heart disease, and a
heart transplant is the only therapeutic choice in
extreme cases. Cardiomyopathies are deﬁned as
diseases of the myocardium associated with cardiac
dysfunction.1) They are classiﬁed into ﬁve types
according to symptomatic features: dilated cardio-
myopathy (DCM), hypertrophic cardiomyopathy
(HCM), restrictive cardiomyopathy, arrhythmogenic
right ventricular cardiomyopathy, and unclassiﬁed.
Of the ﬁve types, DCM and HCM are the most
common. In addition, speciﬁc cardiomyopathies are
also deﬁned as cardiomyopathies with systemic
symptoms and/or those secondary to well-deﬁned
etiologies, e.g., alcoholism and hypertension. Thus,
the etiology of cardiomyopathy is broad and compli-
cated and the development of therapeutic strategies
is therefore quite challenging.
Sugar chains in glycolipids and glycoproteins
play important roles in many biological processes. Six
forms (types I–VI) of O-galactoside ,2,3-sialyltrans-
ferases have been described so far.2)–6) Among them,
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ferases, which mediate the transfer of sialic acid via
an ,2,3-linkage to the galactose residue of terminal
GalO1,3GalNAc structures on O-linked oligosaccha-
rides of glycoproteins or glycolipids. The type II
enzyme (ST3Gal-II) acts on glycolipids and glyco-
proteins in vitro, but is highly expressed in the brain
and has an acceptor substrate preference for glyco-
lipids.3) This result suggests that the enzyme
primarily operates in the biosynthesis of gangliosides,
such as GM1b, GD1a, and GT1b.4),7) The mouse
ST3Gal-II gene is developmentally expressed in the
heart; it can be detected at 3 days old, but there is
only a trace at 21 days and no expression by 49
days.4) The mouse type I enzyme (ST3Gal-I), which
has an acceptor substrate preference for glycopro-
teins, is slightly expressed in the heart.8) In humans,
ST3Gal-II mRNA is highly expressed in the heart
and skeletal muscle, unlike in mice.9) The physio-
logical signiﬁcance of strict temporal control and
species diﬀerences in ST3Gal-II expression remains
unknown.
Protein glycosylation is critical for proper
protein synthesis. Correct folding of secretory or
membrane proteins is achieved in the endoplasmic/
sarcoplasmic reticulum (ER/SR) with the aid of
various molecular chaperones and oxidoreductases,
which are called ER quality control (ERQC)
mechanisms.10) In the system, two lectin-like chaper-
ones, calreticulin and calnexin, bind to monoglycosy-
lated forms of asparagine (N)-linked oligosaccharides.
Calreticulin is a soluble Ca2D-binding chaperone,
located in the ER lumen.11) Calnexin is a Ca2D-
binding chaperone bound to the ER membrane.12)
Thus, perturbation of protein glycosylation can be
estimated by ERQC activity, and the activity can
be monitored by measuring the expression levels of
calreticulin and calnexin.
During the course of our research on sialic acid
metabolism in transgenic mice, we found homozy-
gous-speciﬁc, adult onset cardiac dilatation with
100% incidence in mice of a transgenic line harboring
ST3Gal-II transgenes. The mice showed altered
glycosylation of heart proteins and higher expression
of calreticulin in hearts compared with wild-type
mice, suggesting that the perturbation in protein
glycosylation activated the ERQC machinery, par-
ticularly calreticulin expression, and that the high
level of calreticulin impairs cardiac function. The
mice would serve as a new model for diseases with
cardiac dilatation, such as DCM.
Materials and methods
Mice. All mice were housed under speciﬁc
pathogen-free conditions with food (CMF, Oriental
Yeast Co., Ltd., Tokyo, Japan) and water ad libitum.
C57BL/6CrSlc and Slc:ICR mice were purchased
from Japan SLC Inc. (Hamamatsu, Japan). All
animal experiments were conducted in accordance
with the guidelines for animal experiments of the
National Institute of Infectious Diseases, Tokyo,
Japan and the National Institute of Biomedical
Innovation, Osaka, Japan.
Generation of transgenic mice. The mouse
ST3Gal-II cDNA sequence (GenBank: X76989) was
cloned in our previous study.3) The overexpression
construct was generated by inserting the cDNA
sequence into the multicloning site of a pCAGGS-
based plasmid.13) The SalI-BamHI fragments of the
plasmid (Fig. 1A) were injected into the pronuclei of
C57BL/6CrSlc zygotes. The manipulated embryos
were transferred into the oviducts of pseudopregnant
Slc:ICR mice. Tail DNA of transgenic founder mice
was ﬁrst screened by PCR. Integration of the
transgene into founder candidates was assessed by
Southern blot analysis with EcoRI-digested genomic
DNA (3µg/lane) from 4-week-old mice (probe 1:
SalI-SmaBI fragment of the CAGGS plasmid, 357bp;
probe 2: KpnI-XhoI fragment of ST3Gal-II cDNA,
930bp; Fig. 1A). In our previous study,14) the
insertion site of the transgene was mapped by Blast
search for the ﬂanking sequence of the transgene in
the Ensembl database (http://www.ensembl.org/,
Fig. 1E).
Quantitative analysis of mRNA expressions.
The amounts of ST3Gal-II and /-sarcoglycan (SGCD)
mRNA in tissues of 3-month-old mice were examined
by quantitative RT-PCR analyses with glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA
as an internal control. Total RNA was extracted from
each tissue and cDNA was transcribed from the
total RNA with reverse transcriptase (Superscript II,
Invitrogen Corp., Carlsbad, CA, U.S.A.). Amounts
of transcripts were measured by real-time PCR
using 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, U.S.A.) with
QuantiTect Probe PCR Kits (QIAGEN, Hilden,
Germany) and TaqMan probes (Applied Biosystems)
for three genes.
Protein extraction. The hearts of TG and WT
mice were collected and snap-frozen in liquid nitro-
gen. Heart proteins were extracted by unfractionated
and fractionated methods. Unfractionated heart
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Fig. 1. Production of ST3Gal-II transgenic mice. (A) SalI-BamHI fragments of a pCAGGS-based plasmid containing mouse ST3Gal-II
cDNA were injected into mouse zygotes. (B) Integration of the transgene was conﬁrmed by Southern blot analysis. Lane 1: transgenic
mice, Lane 2: non-transgenic (WT) mice, Lane 3: C57BL/6Cr. M: DNA size markers. (C) Expression of the transgene was conﬁrmed
by TaqMan based quantitative RT-PCR analysis of hearts from homozygous (n F 5), hemizygous (n F 3), and wild (n F 5) mice at 3
months of age. ST3Gal-II expression was normalized with GAPDH expression and displayed as mean ’ S.D. with the average of wild
values as 1. Values with diﬀerent labels (a, b, and c) are signiﬁcantly diﬀerent (p < 0.05). (D) Western blot analysis indicated
signiﬁcantly higher expression (*, p < 0.05) of ST3Gal-II protein in homozygous TG hearts than WT hearts at 10 weeks of age
(n F 3). (E) Our previous study14) indicated that the transgene was inserted at 9200kb upstream of the SGCD gene. (F) No
signiﬁcant diﬀerence in the SGCD expressions in hearts or skeletal muscles (rectus femoris) between TG (n F 4, black bars) and WT
(n F 5, white bars) was found by TaqMan based quantitative RT-PCR analysis of 3-month-old mice. SGCD expression was
normalized with GAPDH expression and displayed as mean ’ S.D. with the average of wild values as 1. (G) Western blot analysis
indicated no signiﬁcant diﬀerence in expression of /-sarcoglycan protein between TG and WT hearts at 10 weeks of age (n F 3).
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Extraction kit (Total protein, Bio-Rad, Hercules,
CA, U.S.A.) for quantitative Western blot analysis
according to the manufacturer’s protocol. Brieﬂy,
each heart was homogenized in 1mL of extraction
buﬀer (7M urea, 2M thiourea, 1% ASB-14, 40mM
Tris, 0.001% bromophenol blue) using a bead mill
(TissueLyzer, QIAGEN). The homogenate was cen-
trifuged (15,000 # g, 5min), and the supernatant
(TP) was collected for further analysis. Fractionated
heart proteins were extracted sequentially for lectin
blot analysis with the ReadyPrep kit (Bio-Rad),
according to the manufacturer’s protocol. Brieﬂy,
each heart was homogenized in 1mL of Buﬀer 1
(40mM Tris, pH 7.4) supplemented with Complete
Protease Inhibitor Mixture (Roche Diagnostics
GmbH, Mannheim, Germany) using a bead mill.
The homogenate was centrifuged (15,000 # g, 5min),
the supernatant (fraction 1) was collected, and the
pellet was re-suspended in 500µL of Buﬀer 2 (8M
urea, 4% CHAPS, 40mM Tris, 2mM tributyl-
phosphine). After centrifugation, the supernatant
(fraction 2) was collected. The protein concentration
of each sample was measured with the EZQ Protein
Quantitation kit (Invitrogen).
Quantitative Western blot analysis. The
amounts of ST3Gal-II, /-sarcoglycan, calreticulin,
and calnexin in unfractionated heart proteins were
examined by quantitative Western blot analyses with
GAPDH as an internal control. Heart proteins were
separated by 4–12% Bis-Tris gel electrophoresis with
MES SDS running buﬀer (Invitrogen), and trans-
ferred onto PVDF membranes (Pall Corp., Port
Washington, NY, U.S.A.). Immunoblots were per-
formed using SNAP i.d. (Millipore Corp., Billerica,
MA, U.S.A.). The membranes were incubated with
primary antibodies against ST3Gal-II (rabbit;
Lifespan BioSciences, Inc., Seattle, WA, U.S.A.), /-
sarcoglycan (rabbit; Santa Cruz Biotechnology,
Santa Cruz, CA, U.S.A.), calreticulin (goat; Santa
Cruz Biotechnology) or calnexin (rabbit; Cell Signal-
ing Technology, Beverly, MA, U.S.A.) and then the
blots were visualized by chemiluminescence (ECL-
plus, GE Healthcare U.K. Ltd., Buckinghamshire,
U.K.) with horseradish peroxidase (HRP)-conjugated
secondary antibodies against rabbit (Vector Labo-
ratories Inc., Burlingame, CA, U.S.A.), or goat IgG
(Jackson ImmunoResearch laboratories Inc., West
Grove, PA, U.S.A.). Blot images were captured by a
CCD camera (LAS-3000, Fujiﬁlm, Tokyo, Japan).
Then, all blots were treated with WB stripping
solution (Nacalai Tesque, Kyoto, Japan), incubated
with mouse anti-GAPDH antibodies (Millipore), and
visualized by chemiluminescence with HRP-conju-
gated secondary antibodies against mouse IgG
(Jackson ImmunoResearch). Blot images were cap-
tured with a CCD camera. The band intensities in
each image were measured with imaging software
(Multigauge, Fujiﬁlm). The amounts of each protein
were calculated as protein/GAPDH ratios.
Clinical observations. The health status of
both TG and WT mice was monitored every week for
1 year. The body weights of three male and three
female WT and homozygous TG mice were also
measured every week from age 40 to 300 days. The
TG homozygous mice with dyspnea were used for
pathological examinations. WT mice of the same age
were used as controls. At necropsy, plasma samples
were collected for plasma biochemical analyses using
the DRI-CHEM 3000V system (Fujiﬁlm Medical Co.
Ltd., Tokyo, Japan).
Pathological examination. Mice were deeply
anesthetized with pentobarbital-sodium (Nembutal,
Abbott, Chicago, IL, U.S.A.). Then, a thoracotomy
was performed. After resecting the thymus, macro-
scopic photographs were taken to measure cardiac
sizes against the thorax width. With these width
parameters, we calculated cardiac dilatation indices
similar to cardiac thoracic ratios, which are often
used at diagnosis with chest radiographs. The
thoracic and abdominal cavities were also examined.
The vena cava was then resected, and the left
ventricle was perfused with PBS and then reperfused
with a 7:3 mixture of 10% neutral-buﬀered formalin
and Carnoy ﬂuid. Hearts were removed and ﬁxed in
neutral buﬀered formalin to present four-chamber
views. The hearts were embedded in paraﬃn using
conventional methods, cut into 3-µm slices, and
specimens were prepared with hematoxylin and eosin
staining. Microscopic images were captured under a
light microscope (BX50, Olympus Corp., Tokyo,
Japan) with a CCD camera (DP25, Olympus).
Ganglioside analysis. Ganglioside fractions
were obtained from heart, cerebrum and liver by the
Folch extraction and partition of total lipids.15) The
pooled upper phase was saponiﬁed with 0.5mL of
0.2N KOH/methanol and desalted with a Sep-Pak
C18 reverse-phase cartridges (Waters Corp., Milford,
MA, U.S.A.).16) Individual gangliosides were sepa-
rated by thin-layer chromatography on a plate
coated with super-ﬁne silica gel 60 (Merck KGaA,
Darmstadt, Germany) with chloroform:metha-
nol:0.2% CaCl2 (60:35:8, by volume) and visualized
with resorcinol reagent.17)
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protein fractions from 10-week-old TG and WT mice
(92µg/lane) were separated by 4–12% Bis-Tris gel
electrophoresis with MES SDS running buﬀer (In-
vitrogen), transferred onto PVDF membranes (Pall).
The protein transfer onto PVDF membranes was
conﬁrmed using a SYPRO Ruby blot stain kit
(Invitrogen) before the lectin blots and the images
were captured by a laser scanner (FX-Pro, Bio-Rad).
Lectin binding assays were performed using SNAP
i.d. (Millipore). For MAA assays, digoxygenin
(DIG)-conjugated lectins (MAA) included in the
DIG glycan diﬀerentiation kit (Roche Diagnostics)
were used with HRP-conjugated anti-DIG antibody
(Jackson ImmunoResearch). For ConA and PNA
blots, ﬂuorescein-conjugated ConA and PNA (Vector
Laboratories) were used with HRP-conjugated anti-
ﬂuorescein antibody (Vector Laboratories). All blots
were visualized with chemiluminescence (ECL-plus)
and their images were captured with a CCD camera.
Lectin staining of heart and skeletal muscle
tissues. The sugar-chain status in frozen sections
(6µm) of hearts and rectus femoris muscles at
10 weeks of age was analyzed by binding of
biotinylated PNA lectins (Vector Laboratories); the
sections were treated with or without ,2,3-sialidase
(5U/mL, Takara Bio Inc., Otsu, Japan). The lectins
were visualized by 0.1mg/mL FITC-avidin D
(Vector Laboratories) under a ﬂuorescence micro-
scope (OPTIPHOTO, Nikon Corp., Tokyo, Japan)
with a digital image capture unit (DXC-S500/OL,
Olympus).
Statistical analyses. Expressions of ST3Gal-II
mRNA (Fig. 1C) were analyzed statistically among
three genotypes using analysis of variance, followed
by pairwise comparisons by the Tukey–Kramer
method. Expressions of SGCD mRNA (Fig. 1F)
and proteins (Figs. 1D, 1G, 6C, and 6D), the heart
and body weight parameters (Fig. 2E), and biochem-
ical analyses (Fig. 2F) were analyzed statistically
between TG and WT mice using Student’s t-test.
Diﬀerences with a p < 0.05 were considered statisti-
cally signiﬁcant. All statistical analyses were con-
ducted using StatView Version 5 (SAS Institute Inc.,
Cary, NC, U.S.A.).
Results
Generation of transgenic mice. Of two
established transgenic lines (4C30 and 4C59), mice
only from 4C30 line exhibited cardiac dilatation and
was used for further studies. The presence of the
transgenes (Fig. 1A) was conﬁrmed by Southern blot
analysis (Fig. 1B), and their expression was con-
ﬁrmed by quantitative RT-PCR (Fig. 1C) and
Western blot analyses (Fig. 1D). Extremely higher
levels of ST3Gal-II expression were found in hearts
of transgenic mice than in those of wild mice. The
mRNA level of ST3Gal-II in the heart was approx-
imately three times higher in homozygous transgenic
mice than in hemizygous transgenic mice. Our
previous study14) showed that the transgene was
inserted at upstream of the /-sarcoglycan (SGCD)
gene (Fig. 1E). However, neither mRNA nor protein
expression of SGCD gene in hearts was inﬂuenced by
genotype (Figs. 1F and 1G).
Clinical observations. All mice of the
homozygous transgenic (TG) line developed severe
cardiac dilatation with dyspnea, deformation of the
thorax, and rapid weight loss at the end-stage
(Fig. 2A). Both wild-type (non-transgenic; WT)
and hemizygous transgenic animals survived without
abnormal symptoms for at least 1 year. The TG mice
were born healthy and grew normally until approx-
imately 150 days (Fig. 2B, 2C). At that point, they
exhibited rapid weight loss and died about a week
after the onset of symptoms. The average life span
of the TG mice was 227 ’ 55 days (mean ’ SD,
Fig. 2D). Approximately one-third of hemizygous
transgenic mice older than 18-months also showed
similar, but milder, cardiac symptoms compared with
the homozygous transgenic mice (data not shown).
Signiﬁcantly increased heart:body weight ratios,
indicating heart enlargement, were already evident
in the TG mice at 4 weeks of age in comparison with
WT mice even though the TG mice showed no
clinical symptoms (Fig. 2E). Biochemical analyses
indicated that the plasma CPK and LDH values were
signiﬁcantly higher in TG mice than in WT mice at 4
weeks of age, long before the onset of symptoms
(Fig. 2F).
Pathological examination. At necropsy of the
TG mice, the hearts were enlarged and occupied a
larger area inside the thorax, with all four chambers
dilated and thin, with low tensile-strength walls
(Fig. 3). Both atria and ventricles of TG hearts were
larger compared with those of the WT hearts. From
the width measurement of hearts and thoraxes, we
calculated cardiac dilatation indices. Mice at 5–6
months of age in the TG group showed signiﬁcantly
larger indices (0.66 ’ 0.44; mean ’ SD, n F 4, range,
0.628–0.723) than those in the WT group (0.451 ’
0.039, n F 3, range, 0.408–0.485). Observation of the
four chambered view of the heart presented ex-
tremely thin atrial walls in the TG group, with a high
O. SUZUKI et al. [Vol. 87, 554degree of dilatation and blood ﬁlling into the inner
space. The left and right ventricles also exhibited
thin free walls and septal walls with a high degree of
dilatation. The papillary muscles in the left ventricles
had also become thin. Except for pulmonary and
hepatic congestion, no abnormality was found in the
thoracic or abdominal cavities.
Our histological observations revealed that the
width of myocardial ﬁbers changed in both left and
right atria as well as ventricular myocardial layers
in TG hearts (Fig. 4). Particularly in ventricular
muscles, thin and thick ﬁbers were mixed, presenting
a degenerated and irregular orientation. In the
myocardium layer, connective tissues with slight
ﬁbrosis were sporadically observed, but there was
no cell inﬁltration. No coronary artery in the atrium,
ventricle, or myocardium presented with luminal
narrowing or obstruction. No apparent abnormality
was found in the myocardium of WT hearts. A survey
of 45 additional organs in TG mice by hematoxylin
and eosin staining revealed severe blood congestion
in the lungs, liver, and spleen, and a slight, mild
degeneration in skeletal muscles but no remarkable
alteration in other organs (data not shown).
Ganglioside analysis. High-performance thin-
layer chromatography analysis showed no diﬀerence
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Fig. 2. (A) Appearance of 6-month-old transgenic (TG) mice homozygous for the ST3Gal-II transgene. Daily body weights gains (B, C)
in TG and WT mice. (D) Kaplan–Meier survival plot for male and female TG mice. All hemizygous transgenic and WT mice survived
until at least 1 year old (not plotted). (E) Body weights, heart weights, and heart:body weight ratios of TG (black bars) and WT
(white bars) mice at 4 weeks of age (mean D SD; n F 3). (F) Biochemical analysis of mouse plasma enzymes (mean D SD; n F 5). Four
enzyme activities were compared in plasma samples from TG (black bars) and WT (white bars) mice at 4 weeks of age. All plasma
enzymes tested showed signiﬁcantly higher activities in TG mice than in WT mice, even at a young age, long before the onset of
symptoms. Asterisks in E and F indicate signiﬁcant diﬀerence between WT and TG mice (n F 3; p < 0.05).
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liver between the TG and WT mice (Fig. 5).
Lectin blot analysis of heart proteins.
Alterations in the sugar moieties of heart glycopro-
teins were examined by lectin blot staining in two
fractions of heart proteins from 10-week-old mice
(Fig. 6A, 6B). Three lectins were used: Maackia
amurensis seed lectins (MAA) recognize ,2,3-sialy-
lation of sugars, such as Gal-GalNAc; peanut lectins
(PNA) recognize non-sialylated Gal-GalNAc sugars;
concanavalin A (ConA) recognizes high-mannose-
type sugars. Staining with MAA and PNA lectins
indicated that heart proteins of TG mice were less
sialylated than those of WT mice, even though
ST3Gal-II was overexpressed in the TG mice. One
diﬀerentially stained ConA band was found in
fraction 1 (soluble proteins containing cytosolic
proteins), indicating that some cytosolic heart
proteins in TG mice lost their high-mannose-type
glycosylation, which was present in those of WT
mice.
Calreticulin and calnexin expression in
hearts. Quantitative Western blots with TG and
Opened 
Thorax 
TG WT
Excised
4-Chamber
 View
Hearts
Fig. 3. The hearts of 6-month-old transgenic (TG) mice homo-
zygous for the ST3Gal-II transgene were much larger than those
of wild-type (WT) mice. TG heart shows severe dilatation of
all four chambers with thin, low tensile-strength walls. Bars F
5mm.
TG
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ventricular
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Fig. 4. Histopathological observations of hearts in 6-month-old transgenic (TG) and wild-type (WT) mice. Hematoxylin and eosin-
stained tissue sections from three cavity walls, the positions of which are indicated by rectangles in the upper images and are shown in
low (middle images, bar F 100µm) and high (lower images, bar F 10µm) magniﬁcations. Slight ﬁbrosis was observed sporadically in
TG hearts, but no apparent cell inﬁltration was found in either TG or WT hearts.
O. SUZUKI et al. [Vol. 87, 556WT heart proteins at 10 weeks of age revealed a
signiﬁcant increase (p < 0.05) in the amounts of
calreticulin and calnexin in the TG heart (Fig. 6C,
6D).
Lectin staining of heart and skeletal muscle
tissues. Sialylation in heart and skeletal muscle
tissues with transgene-derived ST3Gal-II was exam-
ined by histochemical analysis using PNA lectin in
combination with ,2,3-sialidase treatment (Fig. 7).
The ST3Gal-II enzyme converts sugars (GalO1,3Gal-
NAc) that are bound by PNA to sugars (SialGalO1,
3GalNAc) that are not bound by PNA by ,2,3-
sialylation of terminal galactose residues. The ,2,3-
sialidase enzyme reverses the reaction. In the heart,
the staining was essentially the same between TG
and WT mice with and without ,2,3-sialidase
treatment. In contrast, PNA staining in the TG
skeletal muscle tissue was more intense than that in
the WT tissue even without ,2,3-sialidase treatment.
Staining in skeletal muscle tissue was essentially the
same between TG and WT mice after the ,2,3-
sialidase treatment. These results indicated that
most of the terminal GalO1,3GalNAc structures in
pericellular regions (cell membranes and ECM) were
sialylated via the ,2,3 linkage of galactose residues
in the heart. The sialylation decreased in skeletal
muscle of TG mice compared with that in WT mice.
After ,2,3-sialidase treatment, the TG and WT
tissues showed similar staining patterns, indicating
that the diﬀerential staining by PNA without ,2,3-
sialidase treatment was attributable to diﬀerential
,2,3-sialylation of Gal-GalNAc structures and not
diﬀerent amounts of Gal-GalNAc structures.
Discussion
The mice that were homozygous for the ST3Gal-
II transgene developed non-inﬂammatory cardiac
dilatation with relatively late onset and 100%
lethality. Our ﬁndings suggest a new concept that
abnormal glycosylation of heart proteins can cause
cardiac dilatation via perturbation of ER/SR envi-
ronments. Thus, the mice may be a new model for
examining the mechanism and developing therapeu-
tics of non-inﬂammatory cardiac dilatation related to
abnormal glycosylation.
The severity and onset of cardiac symptoms
in 4C30 mice depended on a level of transgene
expression. As a 1-year observation revealed that
cardiac dilatation in 4C30 mice was homozygous-
speciﬁc, we ﬁrst considered two issues with regard to
the possible mechanism of the cardiac dilatation: the
eﬀect of genome disruption by transgene insertion
and the eﬀect of transgene dosage. However, after
longer observation and chromosomal mapping of
the transgene, we concluded that the eﬀect of the
transgene itself was the primary cause for two
reasons. First, some hemizygous transgenic mice
older than 18 months, about three times older than
the homozygous transgenic mice, also showed mild
cardiac symptoms, suggesting that a level of trans-
gene expression, about one third in the hemizygous
compared to that in the homozygous (Fig. 1C), may
be involved in the severity and onset of symptoms.
Second, our previous report on chromosomal map-
ping of the transgene in 4C30 mice by genomic
walking14) indicated that the transgenes were in-
serted into the B1.2 region of chromosome 11,
approximately 200kb upstream of the /-sarcoglycan
gene (Fig. 1E), an area in which no gene has been
reported to date. Decreased /-sarcoglycan expression
was expected in homozygous mice because /-sarco-
glycan is a key component of the sarcomere complex
in muscle tissues and its deﬁciency can cause
degenerative heart diseases, including dilated cardi-
omyopathy.18) However, /-sarcoglycan was equally
expressed in TG and WT mice (Figs. 1F and 1G),
suggesting that the transgene insertion had no
adverse eﬀect on genes near the insertion site in TG
mice.
The histological analysis indicated that TG mice
have cardiac dilatation with a non-inﬂammatory
mechanism. The causes of cardiac dilatation in
humans, such as dilated cardiomyopathies, are not
WT Standard TG
Heart
WT
Brain
WT TG TG
Liver
GM2
GM1
GD1a
GD1b
GT
GM3
Fig. 5. Ganglioside analysis in the brain, liver, and heart. No
diﬀerence in ganglioside composition was found in the brain,
liver, or heart between 6-month-old transgenic (TG) and wild-
type (WT) mice, as analyzed by thin-layer chromatography and
resorcinol staining. The amounts of gangliosides per lane were
equivalent to 1.5mg, 5mg, and 5mg dry weight of the brain,
liver and heart, respectively.
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O. SUZUKI et al. [Vol. 87, 558fully understood. Some are known, such as inﬂam-
mation of the myocardium in viral carditis and loss of
or abnormalities in genes encoding structural pro-
teins, particularly in hereditary cardiomyopathies.19)
However, other idiopathic cardiomyopathies occur,
for which the causes remain unknown. Our TG mice
had no apparent disruption of genes encoding
cardiomuscular proteins and no inﬂammatory re-
sponse in heart tissues. These features suggest that
our TG mice may be useful for examining the
mechanism of some idiopathic cardiomyopathies.
Ganglioside abnormalities are unlikely to cause
heart symptoms in the TG mice because no apparent
change in ganglioside composition was detected in
TG hearts, contrary to our expectation that the
overexpressed ST3Gal-II would increase the content
of sialylated glycolipids, such as GD1a. The absence
of ganglioside changes suggests that the substrate
preference predicted by in vitro experiments4) does
not always coincide with the in vivo situation. The
absence of changes may be because there is little
GM1, a substrate for ST3Gal-II, in mouse hearts.20)
GM3 is a major ganglioside in both mouse and
human hearts.20),21) However, in human hearts, other
gangliosides (GM1, GD1a, GD1b, and GT1b) are
also detected by more sensitive assays with a GM1-
speciﬁc choleragenoid.21) Additionally, GM1 can act
as a cardioprotectant against hypoxic damage in
neonatal rat myocardial cells.22) Thus, further analy-
sis with more sensitive assays is needed to clarify the
possible involvement of ganglioside abnormalities in
cardiomyopathies.
In contrast to gangliosides, the glycosylation of
heart glycoproteins was perturbed in TG mice,
demonstrated by the protein and histochemical
analyses with lectins. The eﬀects of exogenous
ST3Gal-II enzymes induced by transgenesis altered
sugar portions of glycoproteins beyond the reaction
catalyzed directly by the ST3Gal-II enzyme. How-
ever, sialylation changes in an abnormal state might
be diﬃcult to interpret because both skeletal and
heart muscle tissues contain cytosolic sialidases with
high activity at neutral pH.23) Elevated ST3Gal-II
activity induced by transgenesis in TG mice might
cause tissue damage in hearts and skeletal muscles by
higher sialylation. In contrast, if the cytosol is exuded
Fig. 6. Lectin staining of two protein fractions extracted from the hearts of transgenic (TG) and wild-type (WT) mice (n F 3) at 10
weeks of age (A: fraction 1; B: fraction 2). After the conﬁrmation of the presence of proteins on blot membranes by SyproRuby blot
stain (one of three blots is shown for each fraction), the blots were stained with three lectins (ConA, MAA, PNA). Lectin binding was
visualized with chemiluminescence. No evident diﬀerence was found on fraction 2 lectin blots containing proteins with lower solubility
(e.g., membrane proteins). However, some diﬀerentially stained bands (arrows) between TG and WT hearts were found in fraction 1
(soluble proteins): 9100kDa by ConA, and 9250kDa by MAA and PNA. ConA staining indicated that 9100kDa proteins from TG
hearts lost their high-mannose-type glycosylation, which was present in those of WT hearts. PNA staining, which recognizes Gal-
GalNAc sugars, indicated that the sugar portion of the 250-kDa band in WT mice was highly sialylated, and less sialylated in TG
mice. MAA staining, which recognizes ,2,3-sialylation of sugars, such as Gal-GalNAc, conﬁrmed higher sialylation of proteins of the
same size in WT mice than TG mice. Thus, heart proteins in the TG mice were less sialylated than those of WT mice even though
ST3Gal-II, one of the sialyltransferases, was overexpressed in the TG mice. M: Molecular weight markers. Western blots indicate that
heart expression of calreticulin (C) and calnexin (D) were signiﬁcantly higher in the TG hearts than that in WT hearts (p < 0.05).
10 µm
WT TG
10 µm
WT TG A
no enzyme
treated
α2,3-sialidase
treated
B
no enzyme
treated
α2,3-sialidase
treated
Fig. 7. Frozen sections of heart (A) and rectus femoris muscle
(B) treated with or without ,2,3-sialidase and stained with
biotinylated PNA lectin, followed by FITC-avidin D. Bars F
10µm. PNA binding was localized to pericellular regions without
sialidase treatment, whereas the reactivity was essentially the
same between TG and WG hearts. The reactivity in TG muscle
was higher than in WT muscle. After sialidase treatment, PNA
binding in both became evident equally in TG and WT heart
and muscle.
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interstitial spaces of the hearts and muscles, various
cytosolic enzymes, including sialidases, may act on
glycoproteins on the surface of adjacent muscle ﬁbers,
resulting in removal of terminal sialic acids from
glycoproteins, particularly membrane-bound pro-
teins. This tendency was evident in skeletal muscles
(Fig. 7B). Complicated eﬀects of exogenous ST3Gal-
II are also suggested by transfection experiments of
human ST3Gal-II in cell cultures.24) In the experi-
ments, the level of ST3Gal-II mRNA are not
necessary consistent with those of monosialosyl
globopentaosylceramide (MSGb5), a product cata-
lyzed by ST3Gal-II.24) Production of MSGb5 is
highly dependent on cell types used for transfection,
which may be due to cell-type-dependent sialidase
activities.24) In addition, altered protein glycosylation
might be attributed to mislocalization of ST3Gal-II
itself and/or the other glycosyltransferases in the
Golgi apparatus by overloading of exogenous
ST3Gal-II because expression-dependent mislocaliza-
tions were reported for glycosylation-related enzymes
like ,2,6-sialyltransferase,25) GA2/GM2/GD2 syn-
thase,26) and human galactosyltransferase.27) Thus,
the perturbation in the glycoprotein sugar portions
might have been caused by a complex imbalance of
glycosylation–deglycosylation reactions in TG mice.
Elevated calreticulin and calnexin levels in TG
hearts suggest that cardiac dilatation in TG mice is a
response to ER-stress via elevated ERQC, caused by
disorganized protein glycosylation in the ER/SR.
Calreticulin and calnexin participate in a molecular
chaperone system that integrates the processes of N-
glycosylation and ERQC.10) Calreticulin is a multi-
functional protein involved in many functions, such
as regulation of calcium homeostasis,28) ERQC,29)
and interactions with various nuclear hormone
receptors.30) In the heart, calreticulin is highly
expressed in the developing heart, but is strongly
downregulated after birth.31),32) The low level of
calreticulin expression in adult heart is important
for normal heart function because overexpression of
calreticulin in the mouse heart leads to severe cardiac
pathology, such as cardiac chamber dilatation,33)
resulting in complete heart block and sudden
death.34) These harmful eﬀects of calreticulin over-
expression may be due to various forms of ER
stress.35) Myocardiac cells overexpressing calreticulin
are highly susceptible to apoptosis under oxidative
stress.36) The presence of underglycosylated proteins
generates a signal leading to increased GRP78 gene
expression,37) which is an ER stress-associated
protein.38) Thus, ST3Gal-II overexpression in our
TG mice might have perturbed protein glycosylation,
which evoked ER stress and stimulated calreticulin
expression, and the elevated calreticulin may have
caused cardiac dilatation. However, the mechanism is
not so simple, because calreticulin is not always
elevated in dilated hearts; the calreticulin level is not
inﬂuenced in some cases of human dilated cardio-
myopathy.39) Further investigations are needed to
evaluate the involvement of calreticulin in TG hearts.
In conclusion, our transgenic mice (4C30 line)
may represent a new form of cardiac dilatation with
abnormal glycosylation. Although we do not yet have
evidence for a direct connection between abnormal
ST3Gal II expression and cardiac dilatation, our
ﬁndings suggest that the glycosylation status of
heart proteins should be evaluated carefully as a
possible cause of DCM, especially noninﬂammatory
cases, in humans. Our TG mice have potential as a
new animal model for cardiac dilatation diseases,
such as dilated cardiomyopathy, because the mice
can be maintained as a homozygous line with 100%
incidence of heart symptoms and a clear zygosity
check system for the transgene allele is available.14)
The 4C30 strain is available from JCRB Laboratory
Animal Resource Bank at the National Institute of
Biomedical Innovation (http://animal.nibio.go.jp/).
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